Application of Sarcaboside B in medicine used for treating rheumatoid arthritis

An arthritis and rheumatoid technology, applied in the application field of Sarcaboside B in the treatment of rheumatoid arthritis drugs, can solve the problems of poor action selectivity, ulcers, damage to the gastrointestinal mucosa, etc., to achieve outstanding substantive characteristics and inhibitory activity strong effect

Inactive Publication Date: 2013-10-23
丁圣雨
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, for rheumatoid arthritis, non-steroidal anti-inflammatory drugs (diclofenac, aspirin, etc.) and immunosuppressants (6-mercaptopurine, etc.) Gastrointestinal mucosa leads to peptic ulcer, which has poor selectivity and is easy to induce infection, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Sarcaboside B in medicine used for treating rheumatoid arthritis
  • Application of Sarcaboside B in medicine used for treating rheumatoid arthritis
  • Application of Sarcaboside B in medicine used for treating rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Embodiment 1: the preparation of compound Sarcaboside B tablet involved in the present invention:

[0013] Take 20 grams of compound Sarcaboside B, add 180 grams of conventional excipients for tablet preparation, mix well, and make 1000 tablets with a conventional tablet press.

Embodiment 2

[0014] Embodiment 2: the preparation of compound Sarcaboside B capsules involved in the present invention:

[0015] Get 20 grams of compound Sarcaboside B, add conventional auxiliary materials for preparing capsules such as 180 grams of starch, mix well, and pack into capsules to make 1000 tablets.

[0016] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0017] Experimental example 1, the influence of Sarcaboside B of the present invention on rat adjuvant arthritis

[0018] Grind Mycobacterium casei (Difco) and mix it with liquid paraffin to make 10mg / ml, and make Freund's complete adjuvant after autoclaving. Male SD rats were intradermally injected with 50ul of the above-mentioned adjuvant in the right hind paw, and at the same time, injected 50ul intradermally at the tail about 3cm away from the base of the tail. The difference of , represents the degree of swelling. On the 16th day after the injection of the adjuvant, the swelling of the left hind foot of the rats was obvious. The rats were divided into groups according to the degree of swelling and body weight. The experimental group was orally given Sarcaboside B 5.0, 10.0, 20.0 mg / kg of the present invention, and the positive control group was orally given diclofenac 10 mg / kg, the control group was given equal volume of distilled water, once a day, for 7 consecutive day...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Sarcaboside B capable of treating immunity inflammation is used for preparing a medicine used for treating rheumatoid arthritis, terfenadine and diclofenac sodium are taken as contrast, and Sarcaboside B has a definite curative effect. The invention discloses an application of Sarcaboside B in the medicine used for treating rheumatoid arthritis for the first time, a brand new skeleton type is adopted, and Sarcaboside B has unexpected rheumatoid arthritis treatment activity, no probability that any revelation is given by other compounds, outstanding substantial characteristic and an obvious progress when being used for treating rheumatoid arthritis.

Description

technical field [0001] The invention relates to the application of Sarcaboside B in the preparation of medicines for treating rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis is a clinical common disease and frequently-occurring disease. Rheumatoid arthritis belongs to autoimmune disease and belongs to the category of immune inflammation. At present, for rheumatoid arthritis, non-steroidal anti-inflammatory drugs (diclofenac, aspirin, etc.) and immunosuppressants (6-mercaptopurine, etc.) Gastrointestinal mucosa leads to peptic ulcer, which has poor selectivity and is easy to induce infection. Therefore, compounds with well-defined components, controllable quality, safety and high efficiency have potential value in the development of drugs for rheumatoid arthritis. [0003] The compound Sarcaboside B involved in the present invention is a new skeleton compound published in 2012 (Li, X. et al., 2012. Two New-Skeleton Compounds from Sarcandra glabra. H...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P19/02A61P29/00
Inventor 丁圣雨
Owner 丁圣雨
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap